Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Sema4, |
RCV002255968 | SCV002534687 | likely benign | Hereditary cancer-predisposing syndrome | 2020-12-07 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002255968 | SCV002652341 | likely benign | Hereditary cancer-predisposing syndrome | 2021-03-29 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV003094250 | SCV003480789 | uncertain significance | Colorectal cancer, susceptibility to, 10 | 2022-01-15 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). This sequence change replaces leucine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 188 of the POLD1 protein (Silent). This variant has not been reported in the literature in individuals affected with POLD1-related conditions. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |